Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data

References

• Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14(96):109–116. doi:10.1183/09059180.05.00009606
   Google Scholar
• van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26(1):16079. doi:10.1038/npjpcrm.2016.79
   PubMedGoogle Scholar
• Janson C, Henderson R, Lofdahl M, Hedberg M, Sharma R, Wilkinson AJK. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020;75(1):82–84. doi:10.1136/thoraxjnl-2019-213744
   PubMed Web of Science ®Google Scholar
• Jain R, Baylis L, Sutton L, Patel P, Collison K, Sharma R. A meta-analysis of the ease of use and correct use of placebo ELLIPTA dry powder inhaler in subjects with chronic obstructive pulmonary disease. CHEST. 2019;P4220.
   Google Scholar
• Dolovich M. New propellent-free technologies under investigation. J Aerosol Med. 2010;12:S–9.
   Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107. doi:10.1513/AnnalsATS.201702-156PS
   PubMed Web of Science ®Google Scholar
• Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D. In vitro dosing performance of the ELLIPTA(R) Dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the electronic lung (eLung). J Aerosol Med Pulm Drug Deliv. 2015;28(6):498–506. doi:10.1089/jamp.2015.1225
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595. doi:10.2147/COPD.S195438
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Rytila P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257–262. doi:10.2147/COPD.S11474
   PubMedGoogle Scholar
• Chen HI, Kuo CS. Relationship between respiratory muscle function and age, sex, and other factors. J Appl Physiol. 1989;66(2):943–948. doi:10.1152/jappl.1989.66.2.943
   PubMed Web of Science ®Google Scholar
• Dewar MH, Jamieson A, McLean A, Crompton GK. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med. 1999;93(5):342–344. doi:10.1016/S0954-6111(99)90316-5
   PubMed Web of Science ®Google Scholar
• Seheult JN, Costello S, Tee KC, et al. Investigating the relationship between peak inspiratory flow rate and volume of inhalation from a Diskus Inhaler and baseline spirometric parameters: a cross-sectional study. Springerplus. 2014;3(1):496. doi:10.1186/2193-1801-3-496
   PubMedGoogle Scholar
• Prime D, de Backer W, Hamilton M, et al. Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the ELLIPTA(R) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2015;28(6):486–497. doi:10.1089/jamp.2015.1224
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate: an emerging biomarker in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2019;199(12):1577–1579. doi:10.1164/rccm.201901-0005LE
   PubMed Web of Science ®Google Scholar
• Palander A, Mattila T, Karhu M, Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Investig. 2012;20:25–33. doi:10.2165/00044011-200020010-00004
   Web of Science ®Google Scholar
• Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7(1):69–73. doi:10.1183/09031936.94.07010069
   PubMed Web of Science ®Google Scholar
• Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217–224. doi:10.15326/jcopdf.4.3.2017.0183
   PubMed Web of Science ®Google Scholar
• Chen SY, Huang CK, Peng HC, Yu CJ, Chien JY. Inappropriate peak inspiratory flow rate with dry powder inhaler in chronic obstructive pulmonary disease. Sci Rep. 2020;10(1):7271. doi:10.1038/s41598-020-64235-6
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78–83. doi:10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar
• Prime D, Hamilton M, Taylor E. In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles. European Respiratory Journal. 2019;54:PA4230. Presented at the ERS Congress 2019; September–October; 2019:4228–4232; Madrid, Spain.
   Google Scholar
• Prime D, Hamilton M, Patmore D. Consistency of dose delivery of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) across patient relevant inhalation flow rates from a dry-powder inhaler (DPI). CHEST. 2019;156:A1786. doi:10.1016/j.chest.2019.08.1550
   Web of Science ®Google Scholar
• GlaxoSmithKline. Trelegy ELLIPTA US prescribing information; 2020. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trelegy/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF. Accessed September, 2020.
   Google Scholar
• Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two randomized controlled trials. Respir Res. 2020;21(1):131. doi:10.1186/s12931-020-01360-w
   PubMed Web of Science ®Google Scholar
• Heddini A, Sundh J, Ekstrom M, Janson C. Effectiveness trials: critical data to help understand how respiratory medicines really work? Eur Clin Respir J. 2019;6(1):1565804. doi:10.1080/20018525.2019.1565804
   PubMed Web of Science ®Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• Grant AC, Walker R, Hamilton M, Garrill K. The ELLIPTA(R) dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015;28(6):474–485. doi:10.1089/jamp.2015.1223
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report; 2020.
   Google Scholar
• Clement Clarke International Ltd. Disposable inspiratory one-way mouthpiece with in-check DIAL G16, instructions for use; September 2019. Available from: https://www.haag-streit.com/clement-clarke/products/inhaler-technique/in-check-dial-g16/?no_cache=1. Accessed February, 2021.
   Google Scholar
• Sanders MJ. Guiding inspiratory flow: development of the in-check DIAL G16, a tool for improving inhaler technique. Pulm Med. 2017;2017:1495867. doi:10.1155/2017/1495867
   PubMed Web of Science ®Google Scholar
• Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857. doi:10.1016/j.rmed.2019.105857
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100. doi:10.1186/s12890-018-0662-0
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019;6(4).
   Web of Science ®Google Scholar
• Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak inspiratory flows: defining repeatability limits and a predictive equation for different inhalers. Chest. 2020;158(4):1413–1419. doi:10.1016/j.chest.2020.03.072
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Hess DR. Aerosol delivery devices for obstructive lung diseases. Respir Care. 2018;63(6):708–733. doi:10.4187/respcare.06290
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343. doi:10.1164/rccm.201604-0733OC
   PubMed Web of Science ®Google Scholar
• Willard-Grace R, Chirinos C, Wolf J, et al. Lay health coaching to increase appropriate inhaler use in COPD: a Randomized Controlled Trial. Ann Fam Med. 2020;18(1):5–14. doi:10.1370/afm.2461
   PubMed Web of Science ®Google Scholar